Your browser doesn't support javascript.
loading
Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort.
Lüker, Jakob; Sultan, Arian; Sehner, Susanne; Hoffmann, Boris; Servatius, Helge; Willems, Stephan; Steven, Daniel.
Afiliação
  • Lüker J; Department of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany. jakob.lueker@me.com.
  • Sultan A; Department of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
  • Sehner S; University Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
  • Hoffmann B; University Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
  • Servatius H; University Hospital Bern, 3010, Bern, Switzerland.
  • Willems S; University Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
  • Steven D; Department of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Heart Vessels ; 31(10): 1669-75, 2016 Oct.
Article em En | MEDLINE | ID: mdl-26546306
Catheter ablation of complex fractionated atrial electrograms (CFAE), also known as defragmentation ablation, may be considered for the treatment of persistent atrial fibrillation (AF) beyond pulmonary vein isolation (PVI). Concomitant antiarrhythmic drug (AAD) therapy is common, but the relevance of AAD administration and its optimal timing during ablation remain unclear. Therefore, we investigated the use and timing of AADs during defragmentation ablation and their possible implications for AF termination and ablation success in a large cohort of patients. Retrospectively, we included 200 consecutive patients (age: 61 ± 12 years, LA diameter: 47 ± 8 mm) with persistent AF (episode duration 47 ± 72 weeks) who underwent de novo ablation including CFAE ablation. In all patients, PVI was performed prior to CFAE ablation. The use and timing of AADs were registered. The follow-ups consisted of Holter ECGs and clinical visits. Termination of AF was achieved in 132 patients (66 %). Intraprocedural AADs were administered in 168/200 patients (84 %) 45 ± 27 min after completion of PVI. Amiodarone was used in the majority of the patients (160/168). The timing of AAD administration was predicted by the atrial fibrillation cycle length (AFCL). At follow-up, 88 patients (46 %) were free from atrial arrhythmia. Multivariate logistic regression analysis revealed that administration of AAD early after PVI, LA size, duration of AF history, sex and AFCL were predictors of AF termination. The administration of AAD and its timing were not predictive of outcome, and age was the sole independent predictor of AF recurrence. The administration of AAD during ablation was common in this large cohort of persistent AF patients. The choice to administer AAD therapy and the timing of the administration during ablation were influenced by AFCL, and these factors did not significantly influence the moderate single procedure success rate in this retrospective analysis.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Veias Pulmonares / Fibrilação Atrial / Ablação por Cateter / Sistema de Condução Cardíaco / Amiodarona / Antiarrítmicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Heart Vessels Assunto da revista: CARDIOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Veias Pulmonares / Fibrilação Atrial / Ablação por Cateter / Sistema de Condução Cardíaco / Amiodarona / Antiarrítmicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Heart Vessels Assunto da revista: CARDIOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha